糖皮质激素对COVID-19结局的影响:系统评价与Meta分析
该系统评价与Meta分析纳入73项研究、共21,350例COVID-19患者,评估糖皮质激素对死亡率、ICU入住、机械通气及病毒排出的影响。结果显示,在重症COVID-19患者中糖皮质激素显示死亡率获益(OR 0.65;95%CI 0.51-0.83;高剂量或低剂量方案间未观察到有益或有害效应;低剂量糖皮质激素对SARS-CoV-2病毒排出持续时间无显著影响。作者指出高剂量与低剂量方案文献异质性高,需进一步高质量临床试验明确最佳时机与剂量。
要点
- 高剂量或低剂量糖皮质激素方案间未观察到有益或有害效应差异。
- 低剂量糖皮质激素对SARS-CoV-2病毒排出持续时间无显著影响。
- 糖皮质激素在机械通气患者(35.3%)、ICU患者(51.3%)和重症COVID-19患者(40%)中广泛使用。
- 高剂量与低剂量方案文献异质性高,需进一步高质量临床试验明确最佳时机与剂量。
适用人群与场景
- 纳入报告COVID-19患者接受糖皮质激素并设有对照组的已发表文献,共73项研究、21,350例患者。
- 糖皮质激素广泛用于机械通气患者(35.3%)、ICU患者(51.3%)和重症COVID-19患者(40%)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:系统评价与Meta分析,检索PubMed、MEDLINE和EMBASE截至2020年7月22日的已发表文献。
- 共纳入73项研究、21,350例COVID-19患者,比较糖皮质激素组与对照组。
- 次要终点:高剂量或低剂量糖皮质激素方案间未观察到有益或有害效应;低剂量糖皮质激素对SARS-CoV-2病毒排出持续时间无显著影响。
- 局限:高剂量与低剂量糖皮质激素方案的文献异质性高。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析。
- 局限:高剂量与低剂量糖皮质激素方案的文献异质性高;作者呼吁进一步高质量临床试验明确最佳时机与剂量。
对床旁实践的改变
- 在重症COVID-19患者中可考虑使用糖皮质激素以降低死亡率,但高剂量与低剂量方案间未见差异,具体剂量与时机需待进一步高质量临床试验明确。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Since its appearance in late 2019, infections caused by severe acute respiratory syndrome coronavirus 2 have created unprecedented challenges for health systems worldwide. Multiple therapeutic options have been explored, including corticosteroids. Preliminary results of corticosteroids in coronavirus disease 2019 (COVID-19) are encouraging; however, the role of corticosteroids remains controversial.
RESEARCH QUESTION: What is the impact of corticosteroids in mortality, ICU admission, mechanical ventilation, and viral shedding in COVID-19 patients?
STUDY DESIGN AND METHODS: We conducted a systematic review of literature on corticosteroids and COVID-19 in major databases (PubMed, MEDLINE, and EMBASE) of published literature through July 22, 2020, that report outcomes of interest in COVID-19 patients receiving corticosteroids with a comparative group.
RESULTS: A total of 73 studies with 21,350 COVID-19 patients were identified. Corticosteroid use was reported widely in mechanically ventilated patients (35.3%), ICU patients (51.3%), and severe COVID-19 patients (40%). Corticosteroids showed mortality benefit in severelly ill COVID-19 patients (OR, 0.65; 95% CI, 0.51-0.83; P = .0006); however, no beneficial or harmful effects were noted among high-dose or low-dose corticosteroid regimens. Emerging evidence shows that low-dose corticosteroids do not have a significant impact in the duration of SARS-CoV-2 viral shedding. The analysis was limited by highly heterogeneous literature for high-dose and low-dose corticosteroids regimens.
INTERPRETATION: Our results showed evidence of mortality benefit in severely ill COVID-19 patients treated with corticosteroids. Corticosteroids are used widely in COVID-19 patients worldwide, and a rapidly developing global pandemic warrants further high-quality clinical trials to define the most beneficial timing and dosing for corticosteroids.
参考来源
- Cano EJ, Fonseca Fuentes X, Corsini Campioli C, et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2020. PMID: 33129791. doi:10.1016/j.chest.2020.10.054
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。